Edition:
United Kingdom

EyeGate Pharmaceuticals Inc (EYEG.OQ)

EYEG.OQ on NASDAQ Stock Exchange Capital Market

0.60USD
22 Feb 2018
Change (% chg)

$0.00 (+0.03%)
Prev Close
$0.60
Open
$0.60
Day's High
$0.61
Day's Low
$0.59
Volume
11,246
Avg. Vol
48,006
52-wk High
$3.38
52-wk Low
$0.54

Chart for

About

Eyegate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company's lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone... (more)

Overall

Beta: --
Market Cap(Mil.): $20.99
Shares Outstanding(Mil.): 17.20
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.60
EPS (TTM): -- -- --
ROI: -- 14.90 10.66
ROE: -- 16.41 14.30

BRIEF-Eyegate Announces Top-Line Results For Phase 2B Trial Of EGP-437 In Cataract Surgery

* EYEGATE ANNOUNCES TOP-LINE RESULTS FOR PHASE 2B TRIAL OF EGP-437 IN CATARACT SURGERY

05 Feb 2018

BRIEF-Eyegate Promotes Sarah Romano To CFO

* EYEGATE PHARMACEUTICALS-ANNOUNCED PROMOTION OF SARAH ROMANO FROM INTERIM CFO TO CFO, EFFECTIVE JANUARY 1, 2018 Source text for Eikon: Further company coverage:

04 Jan 2018

BRIEF-EyeGate Achieves 75 Pct Enrollment In Pivotal Phase 3 Clinical Trial For Anterior Uveitis Triggering Milestone Payment

* EYEGATE ACHIEVES 75% ENROLLMENT IN PIVOTAL PHASE 3 CLINICAL TRIAL FOR ANTERIOR UVEITIS TRIGGERING MILESTONE PAYMENT

18 Dec 2017

BRIEF-Eyegate Pharmaceuticals posts Q3 ‍net loss $4.1 mln vs $3.4 mln a year ago

* Eyegate Pharmaceuticals reports third quarter 2017 financial results and provides business update

14 Nov 2017

BRIEF-EyeGate completes enrollment in phase 2b clinical trial of EGP-437 for cataract surgery

* EyeGate completes enrollment in phase 2b clinical trial of EGP-437 for cataract surgery

08 Nov 2017

Earnings vs. Estimates